Advertisement
Australia markets closed
  • ALL ORDS

    8,153.70
    +80.10 (+0.99%)
     
  • ASX 200

    7,896.90
    +77.30 (+0.99%)
     
  • AUD/USD

    0.6518
    -0.0018 (-0.28%)
     
  • OIL

    83.05
    +1.70 (+2.09%)
     
  • GOLD

    2,241.60
    +28.90 (+1.31%)
     
  • Bitcoin AUD

    108,474.52
    +3,225.53 (+3.06%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • AUD/EUR

    0.6039
    +0.0008 (+0.14%)
     
  • AUD/NZD

    1.0906
    +0.0026 (+0.24%)
     
  • NZX 50

    12,105.29
    +94.63 (+0.79%)
     
  • NASDAQ

    18,276.38
    -4.46 (-0.02%)
     
  • FTSE

    7,952.62
    +20.64 (+0.26%)
     
  • Dow Jones

    39,834.03
    +73.95 (+0.19%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     

Is There Now An Opportunity In Trinity Biotech plc (NASDAQ:TRIB)?

Trinity Biotech plc (NASDAQ:TRIB), might not be a large cap stock, but it received a lot of attention from a substantial price movement on the NASDAQGS over the last few months, increasing to US$1.44 at one point, and dropping to the lows of US$1.21. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether Trinity Biotech's current trading price of US$1.33 reflective of the actual value of the small-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at Trinity Biotech’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change.

View our latest analysis for Trinity Biotech

Is Trinity Biotech Still Cheap?

According to my valuation model, Trinity Biotech seems to be fairly priced at around 3.77% above my intrinsic value, which means if you buy Trinity Biotech today, you’d be paying a relatively fair price for it. And if you believe that the stock is really worth $1.28, there’s only an insignificant downside when the price falls to its real value. Is there another opportunity to buy low in the future? Since Trinity Biotech’s share price is quite volatile, we could potentially see it sink lower (or rise higher) in the future, giving us another chance to buy. This is based on its high beta, which is a good indicator for how much the stock moves relative to the rest of the market.

Can we expect growth from Trinity Biotech?

earnings-and-revenue-growth
earnings-and-revenue-growth

Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. With profit expected to grow by 90% over the next year, the near-term future seems bright for Trinity Biotech. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation.

What This Means For You

Are you a shareholder? It seems like the market has already priced in TRIB’s positive outlook, with shares trading around its fair value. However, there are also other important factors which we haven’t considered today, such as the financial strength of the company. Have these factors changed since the last time you looked at the stock? Will you have enough confidence to invest in the company should the price drop below its fair value?

ADVERTISEMENT

Are you a potential investor? If you’ve been keeping tabs on TRIB, now may not be the most optimal time to buy, given it is trading around its fair value. However, the optimistic prospect is encouraging for the company, which means it’s worth diving deeper into other factors such as the strength of its balance sheet, in order to take advantage of the next price drop.

So while earnings quality is important, it's equally important to consider the risks facing Trinity Biotech at this point in time. Be aware that Trinity Biotech is showing 3 warning signs in our investment analysis and 1 of those can't be ignored...

If you are no longer interested in Trinity Biotech, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here